GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Antibiotice SA (BSE:ATB) » Definitions » Total Liabilities

Antibiotice (BSE:ATB) Total Liabilities : lei419.2 Mil (As of Mar. 2025)


View and export this data going back to 1997. Start your Free Trial

What is Antibiotice Total Liabilities?

Antibiotice's Total Liabilities for the quarter that ended in Mar. 2025 was lei419.2 Mil.

Antibiotice's quarterly Total Liabilities increased from Sep. 2024 (lei361.97 Mil) to Dec. 2024 (lei384.95 Mil) and increased from Dec. 2024 (lei384.95 Mil) to Mar. 2025 (lei419.17 Mil).

Antibiotice's annual Total Liabilities increased from Dec. 2022 (lei243.34 Mil) to Dec. 2023 (lei292.21 Mil) and increased from Dec. 2023 (lei292.21 Mil) to Dec. 2024 (lei384.95 Mil).


Antibiotice Total Liabilities Historical Data

The historical data trend for Antibiotice's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibiotice Total Liabilities Chart

Antibiotice Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 285.73 290.40 243.34 292.21 384.95

Antibiotice Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 289.11 399.50 361.97 384.95 419.17

Antibiotice Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Antibiotice's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=235.055+(85.715+64.178
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=384.9

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=1279.257-894.309
=384.9

Antibiotice's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=207.635+(147.721+63.809
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=419.2

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=1346.113-926.948
=419.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antibiotice Total Liabilities Related Terms

Thank you for viewing the detailed overview of Antibiotice's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibiotice Business Description

Traded in Other Exchanges
N/A
Address
1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).

Antibiotice Headlines

No Headlines